Industry-Sponsored Satellite Symposia

Open to all ACG 2020 attendees, industry-sponsored satellite symposia provide additional educational opportunities for attendees. These programs are independent of the Virtual ACG 2020 Annual Scientific Meeting & Postgraduate Course programs. The ACG is not the continuing medical education provider of these programs. These programs are listed in the Sessions section of the virtual platform and are open to all attendees. To register, add the program to your schedule within the virtual platform. All times are listed as Eastern Time.


A Focus on Type 2 Inflammation in Eosinophilic Esophagitis (EoE)

Jonathan Spergel, MD
11:00 am – 12:30 pm
Hear an expert review the disease presentation of Eosinophilic Esophagitis (EoE) and the role of Type 2 inflammation. Our speaker will describe the nature of coexisting Type 2 diseases in patients with EoE and discuss the roles of epithelial barrier dysfunction, eosinophilic inflammation, and allergic inflammation in EoE.
This program is sponsored by Sanofi Genzyme and Regeneron.

Eosinophilic Esophagitis - Updated Guidelines and Therapeutic Advances to Manage an Evolving Disease

Ikuo Hirano, MD, FACG, Mirna Chehade, MD, MPH, Evan S. Dellon, MD, MPH, FACG
12:30 pm – 2:00 pm
In this, CME Virtual Satellite Symposium, expert faculty will provide guidance on the criteria for diagnosing Eosinophilic esophagitis (EoE) as well as review the updated guideline recommendations and treatment options for the optimal management of patients with EoE. Add this CME Virtual Satellite Symposium to your Virtual ACG 2020 schedule!
This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.


Rethinking CSID: Time for a Paradigm Shift?

Brooks D. Cash, MD, FACG, William D. Chey, MD, FACG, Anthony J. Lembo, MD, FACG, Daksesh B. Patel, DO
4:15 pm – 5:45 pm
Once believed to be a rare disorder, congenital sucrase-isomaltase deficiency (CSID) is increasingly recognized as an overlooked cause of unresolved GI symptoms in patients diagnosed with and treated for various functional gastrointestinal disorders. This genetic condition is characterized by reduced or absent sucrase-isomaltase enzyme activity, leading to undigested sugars and starches in the small intestine and colon and symptoms associated with carbohydrate malabsorption such as chronic diarrhea, abdominal pain, gas and bloating. Click here for more information and to register.
This program is sponsored by QOL Medical.


An Evolution in Microbiota Restoration: Approaches and Results in C. difficile

Paul Feuerstadt, MD, FACG, Sahil Khanna, MD, MBBS, MS, FACG, Gautam Mankaney, MD
4:45 pm – 6:15 pm
Join us for a live virtual symposium with an expert faculty panel as they discuss microbiota restoration therapy for C. difficile infection. Topics will include a comprehensive review of the evolution of fecal microbiota transplantation for C. difficle infection and a look into the next frontier of microbiota restoration therapies. Faculty will contextualize these results and discuss what the next year may look like. Click here for additional information.
Supported by an educational grant from Ferring Pharmaceuticals, Inc.

Transitioning Treatment Through New Immunological Pathways in Inflammatory Bowel Disease

William J. Sandborn, MD, FACG, Kim L. Isaacs, MD, PhD, FACG, Bruce E. Sands, MD, MS, FACG
6:15 pm – 7:45 pm
Drs. Sandborn, Isaacs, and Sands will summarize new evidence on investigational agents with unique mechanisms of action that are in late-stage development for the treatment of moderate-to-severe inflammatory bowel disease (IBD). They will evaluate the most recent clinical findings on the safety and efficacy of therapies that target immunological pathways. They will also assess therapeutic regimens for moderate-to-severe IBD for their ability to improve outcomes in patients who are tumor necrosis factor (TNF) inhibitor-naïve or have previously received TNF inhibitors.
This activity is supported by an educational grant from Genentech, Inc.


Integrating Biosimilars in the Management of IBD: Navigating the Maze

David T. Rubin, MD, FACG, Bincy P. Abraham, MD, MS, FACG
12:30 pm – 2:00 pm
In this symposium, Drs David Rubin and Bincy Abraham, 2 experts on biosimilars for inflammatory bowel disease (IBD), review the science and regulation of biosimilars, discuss strategies for integrating biosimilars into clinical practice, and share tips for gaining patient and clinician acceptance of these therapies.
This program is supported by an independent educational grant from Samsung Bioepis.

Keeping Tabs on Colonoscopy Prep

Douglas K. Rex, MD, MACP, MACG, Jack A. Di Palma, MD, MACG, Lawrence R. Schiller, MD, MACG, Mark B. Cleveland, PhD
6:30 pm – 8:00 pm
Tablet bowel preparations may help offset patient avoidance of colonoscopy or inadequate cleansing through improved palatability compared with liquid products. This session reviews the rationale for using tablet preparations; efficacy, safety, and tolerability data for current and emerging tablet formulations; and how to discuss this option with patients and other providers. Click here for additional information.
Supported by an educational grant from Braintree, A Part of Sebela Pharmaceuticals.


Clinical Review of an Oral Prescription Treatment Option for Adults With Ulcerative Colitis

Bincy P. Abraham, MD, MS, FACG, Michael V. Chiorean, MD, FACG
12:30 pm – 2:00 pm
Drs. Bincy Abraham and Michael Chiorean will discuss the clinical data and safety profile of a prescription treatment for adult patients with moderately to severely active UC.
This program is sponsored by Pfizer.

Raising the Bar for Diagnosis & Management of Gastroparesis: Current Understanding in 2020

Thomas Abell, MD, Linda Anh B. Nguyen, MD, Henry P. Parkman, MD, FACG
6:30 pm – 7:30 pm
Educational Objectives: Briefly describe the pathophysiology and clinical presentation of gastroparesis, highlight the burden of gastroparesis on patients and healthcare systems and illustrate the challenges in diagnosis and long-term management.
This program is sponsored by Takeda Pharmaceuticals U.S.A., Inc.